RCS - Nuformix PLC - Oxilio NXP-001 formulation development contract

NuformixAnnouncement

08/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220208:nRSH9494Aa&default-theme=true

RNS Number : 9494A  Nuformix PLC  08 February 2022

REACH

 

8 February 2022

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Oxilio signs a significant service contract with Quotient Sciences to support
the formulation development of NXP-001

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce that following the Company's signing of an exclusive global licensing
agreement with Oxilio Ltd ("Oxilio") for NXP001 on 13 September 2021, Oxilio
has progressed the product and signed a significant service contract with
Quotient Sciences Ltd ("Quotient Sciences") to support the formulation
development of NXP001. NXP001 is a proprietary new form of aprepitant which is
currently marketed for cancer chemotherapy induced nausea and vomiting
("CINV").

 

Under the contract Oxilio will work with Quotient Sciences, a drug development
and manufacturing accelerator, to identify and evaluate the cocrystal
formulation of aprepitant to deliver optimal bioavailability for the treatment
of CINV.

 

Quotient has prior experience of working with the Nuformix NXP-001 co-crystal
and previously developed a capsule and a powder for oral suspension
formulation, evaluating its performance in a relative bioavailability study
versus EMEND (a branded aprepitant).

 

Quotient will prepare for Oxilio CMC (chemistry, manufacturing and controls)
batches and stability data to support a clinical trial application for the new
formulation of NXP001.

 

The Company looks forward to providing further updates on Oxilio's progress
with NXP001 in due course.

 

Commenting, Alastair Riddell, Executive Chairman of Nuformix, said: "We are
very pleased to see the progress Oxilio is making with NXP001.  Under the
exclusive licence we signed with Oxilio we received an upfront payment, expect
to receive milestone payments when the product completes clinical trials and
ultimately royalties on any sales.  This arrangement is allowing Oxilio to
progress NXP001 without cost to the Company whilst we focus on progressing our
two lead assets, NXP002 and NXP004.  In relation to NXP002 and NXP004 we
continue to make significant progress and I look forward to making further
announcements in due course."

 

Enquiries:

 

 Nuformix plc
 Dr Alastair Riddell, Executive Chairman           Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical and Phase
I-ready assets with potential for significant value and early licensing
opportunities.

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEANAXEFSAEFA